Cartherics
Notting Hill, Australia· Est.
Australian biotech delivering off‑the‑shelf CAR‑NK and EV immunotherapies for women’s cancers and endometriosis.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian biotech delivering off‑the‑shelf CAR‑NK and EV immunotherapies for women’s cancers and endometriosis.
OncologyGynecologyImmunology
Technology Platform
Allogeneic CAR‑NK cells and extracellular vesicles (EVs) engineered via gene‑editing and CAR technology for off‑the‑shelf immunotherapy.
Opportunities
First‑to‑market off‑the‑shelf NK/EV therapies for women’s cancers and endometriosis, plus expansion into neurological disorders via Evinco Therapeutics.
Risk Factors
Regulatory uncertainty for allogeneic cell products, scale‑up manufacturing challenges, and intense competition from established NK cell platforms.
Competitive Landscape
Competes with allogeneic NK cell developers such as Nkarta, Fate Therapeutics, and Celyad, but differentiates through a women‑health focus and inclusion of EV‑based therapeutics.